Publication:
Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival

Simple item page
dc.contributor.authorMora, Bárbara
dc.contributor.authorReyes, María
dc.contributor.authorLobos, Lorena
dc.contributor.authorDel Campo, Matías
dc.contributor.authorBuchegger, Kurt
dc.contributor.authorZanella, Louise
dc.contributor.authorRiquelme, Ismael
dc.contributor.authorIli, Carmen
dc.contributor.authorBrebi, Priscilla
dc.date.accessioned2026-08-11T21:44:54Z
dc.date.available2026-08-11T21:44:54Z
dc.date.issued2025
dc.description.abstractBackground: Gastric cancer (GC) is a significant cancer-related cause of death worldwide. GC's most used chemotherapeutic regimen is based on platinum drugs such as cisplatin (CDDP). However, CDDP chemoresistance reduces the survival rate of advanced GC. The immune C-C chemokine receptor type 5 (CCR5) have been proposed as a pivotal factor in cancer progression since its blockade has been linked with antineoplastic effects on tumor cell proliferation; nevertheless, its role in the chemoresistance of GC has not been elucidated. This study aimed to determine the effects induced by the CCR5 using Maraviroc (MVC), a highly selective CCR5 antagonist, on CDDP-resistant AGS cells (AGS R-CDDP), tumoroids (3D tumor spheroids), and animal models. Results: The combined CDDP and MVC treatment reduced cell viability and inhibited tumoroid formation in AGS R-CDDP cells. The effects of the MVC/CDDP combination on apoptosis and cell cycle progression were correlated with the increase in CDDP (dose-dependent). The mRNA levels of C-C Motif Chemokine Ligand 5 (CCL5), the main ligand for CCR5, decreased significantly in cells treated with the MVC/CDDP combination. MVC in the MVC/CDDP combination improved the survival rate and biochemical parameters of CDDP-treated mice by reducing the side effects of CDDP alone. Conclusions: This finding suggests that MVC/CDDP combination could be a potential complementary therapy for GC.
dc.description.versionVersión Publicada
dc.identifier.citationMora-Lagos B, Reyes ME, Lobos-Gonzalez L, Del Campo M, Buchegger K, Zanella L, Riquelme I, Ili CG, Brebi P. Maraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival. Biol Res. 2025 Jan 18;58(1):4. doi: 10.1186/s40659-024-00581-3
dc.identifier.doihttps://doi.org/10.1186/s40659-024-00581-3
dc.identifier.urihttps://hdl.handle.net/11447/10999
dc.language.isoen
dc.subjectC-C chemokine receptor type 5 (CCR5)
dc.subjectC-C motif chemokine ligand 5 (CCL5)
dc.subjectChemoresistance
dc.subjectCisplatin (CDDP)
dc.subjectGastric cancer (GC)
dc.subjectMaraviroc (MVC)
dc.titleMaraviroc/cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceBiological research
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Maraviroc cisplatin combination inhibits gastric cancer tumoroid growth and improves mice survival.pdf
Size:
3.12 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services